CACLP - The largest IVD Expo & Conference

YHLO Received 651 Million (CNY) Orders in One Week

Industry news | 21 February, 2022 | CACLP

On the evening of February 18, Shenzhen YHLO Biotech Co., Ltd. (hereinafter referred to as "YHLO") announced that it received a purchase order from the Institute of Medical Biology Co., Ltd. (hereinafter referred to as "MBL"). According to the purchase order, MBL will purchase antigen test kits from the YHLO, the total amount is US$50,000,000 (excluding shipping and insurance), or approximately CNY 316 million.

 

It is worth noting that YHLO has received an order of CNY 300 million five days ago. Combined with the amount of this additional order, the total amount of MBL purchase orders received so far is US$102,941,700, or approximately CNY 651 million. With the layout and implementation of globalization strategy in recent years, YHLO overseas business has opened a new era.

 

In addition, YHLO announced its performance report on the same day. Affected by factors such as the overall recovery of the domestic economy and the gradual increase in the installed capacity of instruments and terminal consumption, the company will achieve an operating income of CNY 1,189,442,200 in 2021, a year-on-year increase of 19.06%. The two orders of MBL will bring revenue of about CNY 651 million, which has reached 55% of the operating income of last year.

 

YHLO’s products have also been publicly recognized by Tatsuhiko Kodama, an honorary professor at the Advanced Science and Technology Research Center of the University of Tokyo, Japan. He organized seven top university hospitals and research institutions, including Tokyo University Hospital and Keio University Hospital, specifically for this purpose.

 

A scientific research group has been established to jointly use YHLO’s products to fight the epidemic in Japan, which has appeared in the reports of authoritative media such as Japan's NHK TV and Asahi Shimbun many times. YHLO also stated in the announcement that the fulfillment of this order will have a positive impact on the company's operating performance in 2022, which will help enhance brand influence, profitability and core competitiveness. At the same time, the implementation of this order will have a positive impact on its expansion of overseas markets, especially the Japanese market.

Filed under:
FDA
Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference